Hologic

Hologic, Inc. stands as a pioneering medical technology company dedicated to advancing women's health worldwide through innovation in diagnostics, medical imaging, and surgical products. Founded in 1985 by physicists Jay A. Stein and S. David Ellenbogen in Bedford, Massachusetts, the company began with a singular focus on developing bone densitometry systems to diagnose osteoporosis. Nearly four decades later, Hologic has evolved into a global leader in women's health technology, impacting more than 193 million lives in 2024 through its comprehensive portfolio of breakthrough diagnostic and medical imaging solutions. Headquartered in Marlborough, Massachusetts, Hologic operates through four primary business segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health, serving healthcare providers across over 36 countries with a workforce of approximately 7,000 employees.

Under the leadership of Chairman, President, and CEO Stephen P. MacMillan since 2013, Hologic has transformed from a specialized imaging company into a diversified medical technology powerhouse through strategic acquisitions and organic innovation. The company's pivotal acquisitions of Cytyc Corporation in 2007 and Gen-Probe for $3.7 billion in 2012 fundamentally reshaped its business model, establishing Hologic as the largest diagnostics company focused on women's health. These transformational deals added the ThinPrep Pap test—now the world's most widely used cervical cancer screening test—and molecular diagnostics capabilities that position Hologic at the forefront of early disease detection. The company's Genius 3D Mammography technology, which detects 20-65% more invasive breast cancers than conventional 2D mammograms, exemplifies Hologic's commitment to advancing diagnostic accuracy and improving patient outcomes.

Hologic's business strategy emphasizes innovation across the continuum of women's health care, from screening and diagnosis to treatment and surgery. The company's Breast Health segment includes industry-leading products such as the Genius AI Detection technology—a deep-learning algorithm that aids radiologists in breast cancer detection—and comprehensive breast biopsy and surgical guidance systems. The Diagnostics segment encompasses molecular diagnostic instrumentation, including the ThinPrep system and HPV testing platforms acquired through Third Wave Technologies in 2008. The GYN Surgical segment offers products for endometrial ablation and fibroid treatment, recently strengthened by the 2025 acquisition of Gynesonics and its Sonata transcervical fibroid treatment system for $350 million. The Skeletal Health segment maintains Hologic's original bone densitometry franchise with QDR Bone Densitometer Systems that remain the gold standard for osteoporosis diagnosis.

Financially, Hologic demonstrated solid performance in fiscal year 2024 with total revenue of $4.03 billion and non-GAAP earnings per share of $4.08, reflecting the company's resilient business model and market leadership positions. The company's strong cash generation—with Q4 2024 operating cash flow of $367.1 million—enables continued investment in research and development while returning capital to shareholders through share repurchases totaling $808 million across 11.2 million shares in fiscal 2024. With a market capitalization of approximately $16.68 billion as of December 2025, Hologic trades on the NASDAQ under the ticker symbol HOLX. The company's workplace culture has earned recognition with a 90% employee satisfaction rating according to Great Place to Work surveys and the Gallup Exceptional Workplace Award for three consecutive years, reaching the 97th percentile ranking with 74% employee engagement.

Looking ahead, Hologic's strategic priorities focus on expanding its women's health portfolio through targeted acquisitions and organic innovation, advancing artificial intelligence applications in diagnostic imaging, and penetrating international markets with its proven technologies. Recent developments include the July 2024 completion of the Endomagnetics acquisition for $310 million, adding Magseed and Magtrace breast surgery technologies, and FDA clearances for advanced AI algorithms in cervical cancer screening. In October 2025, Hologic agreed to be acquired by private equity firms Blackstone and TPG in an $18.3 billion transaction including debt, marking a new chapter for the company as it transitions back to private ownership to accelerate innovation and strategic investments in women's health technology. This proposed take-private transaction reflects investor confidence in Hologic's market position, technology leadership, and growth potential in addressing the global need for advanced women's health solutions.